Protocol: L039M
______________________________________________________________________________
| 595 |L04AA11| ETANERCEPTUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA11 ETANERCEPTUM PULB. + SOLV. PT. 25 mg
SOL. INJ.
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT.
SOL. INJ. 50 mg
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB. + SOLV. PT. 25 mg
SOL. INJ.
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT. 50 mg
SOL. INJ.
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 25 mg
PREUMPLUTĂ
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 50 mg
PREUMPLUTĂ
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
________________________________________________________________________________
SUBLISTA C1 - G31F PSORIAZIS CRONIC SEVER (PLACI).
Dostları ilə paylaş: | 
